NCT00410826 - Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2012

Conditions

Stage III Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the LarynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the NasopharynxStage III Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the Oropharynx

Interventions

DRUG

erlotinib hydrochloride

Given orally

DRUG

cisplatin

Given IV

RADIATION

3-dimensional conformal radiation therapy

35 fractions

RADIATION

intensity-modulated radiation therapy

35 fractions

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (9)

27599

University of North Carolina, Chapel Hill

28401

New Hanover Radiation Oncology Center, Wilmington

29425

Medical University of South Carolina, Charleston

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

38104

University of Tennessee Cancer Institute-Boston Cancer Group PLC, Memphis

87131

University of New Mexico Health Science CCOP, Albuquerque

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

98415

Multicare Health System, Tacoma

99508

Alaska Oncology and Hematology LLC, Anchorage

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER